Welcome to INSUPPORT®
INSUPPORT® was created by Indivior to provide information on the access and reimbursement processes on behalf of patients.
Please see the full Prescribing Information including BOXED WARNING for Sublocade (buprenorphine) injection for subcutaneous use (CIII), Important Safety Information for Sublocade and Medication Guide for SUBLOCADE® (buprenorphine extended-release) injection, for subcutaneous use, CIII.
BOXED WARNING
WARNING: RISK OF SERIOUS HARM OR DEATH WITH INTRAVENOUS ADMINISTRATION; SUBLOCADE RISK EVALUATION AND MITIGATION STRATEGY
Serious harm or death could result if administered intravenously. SUBLOCADE forms a solid mass upon contact with body fluids and may cause occlusion, local tissue damage, and thrombo-embolic events, including life threatening pulmonary emboli, if administered intravenously.
Because of the risk of serious harm or death that could result from intravenous self-administration, SUBLOCADE is only available through a restricted program called the SUBLOCADE REMS Program. Healthcare settings and pharmacies that order and dispense SUBLOCADE must be certified in this program and comply with the REMS requirements.
Please see the full Prescribing Information for Suboxone (buprenorphine and naloxone) Sublingual Film (CIII), Important Safety Information for Suboxone, and Medication Guide for SUBOXONE (buprenorphine and naloxone) Sublingual Film®, CIII.
Please see the full Prescribing Information including BOXED WARNING for Perseris (risperidone) for extended-release injectable suspension and Important Safety Information for PERSERIS® (risperidone) for extended-release injectable suspension.
BOXED WARNING
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. PERSERIS is not approved for the treatment of patients with dementia-related psychosis.